Previous 10 | Next 10 |
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced to...
Aclaris Therapeutics (NASDAQ: ACRS ) +73% on positive A-101 data . More news on: Aclaris Therapeutics, Inc., Capricor Therapeutics, Inc., Ocean Power Technologies, Inc., Stocks on the move, Read more ...
LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announ...
The following slide deck was published by Capricor Therapeutics, Inc. in conjunction with this Read more ...
LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announce...
Capricor Therapeutics, Inc. (CAPR) Q2 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Linda Marbán – Chief Executive Officer AJ Bergmann – Chief Financial Officer Conference Call Participants Adheip Mally – Maxim Group ...
Capricor Therapeutics (NASDAQ: CAPR ): Q2 GAAP EPS of -$0.59 beats by $0.21 . More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Positive Results from HOPE-2 Interim Analysis Reported in July To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first...
LOS ANGELES, July 30, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its secon...
EDAP TMS S.A. (NASDAQ: EDAP ) +20% on preliminary Q2 revenue growth . More news on: EDAP TMS S.A., Diebold Nixdorf, Incorporated, Capricor Therapeutics, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...